Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Clinician's Roundtable
Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Peter Buch, MD, FACG, AGAF, FACP; Mallik Greene, PhD
- Peter Buch, MD, FACG, AGAF, FACP
- Mallik Greene, PhD
- Jordan Karlitz, MD
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Project Oncology®
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Lajos Pusztai, MD, DPhil
- Lajos Pusztai, MD, DPhil
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Project Oncology®
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Lajos Pusztai, MD, DPhil
- Lajos Pusztai, MD, DPhil
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
CME/CE Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
1.00 credit
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Project Oncology®
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP; Wassim Mchayleh, MD, MBA, FACP
- Charles Turck, PharmD, BCPS, BCCCP
- Wassim Mchayleh, MD, MBA, FACP
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits

Medical News

Medical News
More Negative Sentinel Nodes Didn’t Improve Breast Cancer Outcomes
09/04/2026
Read more
Medical News
Real-World ALK TKI Outcomes in Metastatic NSCLC
09/04/2026
Read more
Medical News
Predicting Pneumonia After Brain Tumor Surgery
09/04/2026
Read more
Medical News
Fruit, Vegetables and NMIBC Recurrence Risk
09/04/2026
Read more

CME/CE

The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits
MinuteCE®
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 credits 4 episodes
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 credits 4 episodes
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CE
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
1.00 credit
- Sagar Lonial, MD, FACP
1.00 credit

Clinical Practice

Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Project Oncology®
Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Triparna Sen, PhD
- Triparna Sen, PhD
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
0.75 program credits
- Saad Z. Usmani, MD, MBA
0.75 program credits

Programs

A Look at WCLC 2026: Pivotal Trials and Emerging Directions
A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Project Oncology®
A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Triparna Sen, PhD
- Triparna Sen, PhD
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Project Oncology®
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Shelina Ramnarine, PhD; Mohamed Abdelbaki, MD
- Shelina Ramnarine, PhD
- Mohamed Abdelbaki, MD
Supporting Patients Throughout Urothelial Carcinoma Treatment
Supporting Patients Throughout Urothelial Carcinoma Treatment
Project Oncology®
Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Project Oncology®
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD